drugset
drugset / Trial / NCT05675787

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

NCT05675787 ↗

Phase 2 Recruiting 82 enrolled Peking University People's Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

Timeline

Start
2023-01-06
Primary completion
2025-08-31
Completion
2025-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg Oral
Subject medroxyprogesterone acetate Other / unclassified 250 mg Oral
Subject medroxyprogesterone acetate Other / unclassified 500 mg Oral

Indications

atypical endometrial hyperplasia endometrial carcinoma